Yinhu Qingwen Granula for the Treatment of Severe CoVID-19

• ClinicalTrials.gov Identifier: NCT04310865
• Recruitment Status: Suspended
• First Posted: March 17, 2020
• Last Update Posted: July 7, 2021
• Sponsor: Zhong Wang
• Collaborators: Wuhan Leishenshan Hospital; The First Affiliated Hospital of Dalian Medical University; Tanshan People's Hospital; North China University of Science and Technology Affiliated Hospital; Jizhong Energy Fengfeng Group Hospital
• Information provided by (Responsible Party): Zhong Wang, China Academy of Chinese Medical Sciences

Study Description

Brief Summary:

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Granula as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this adaptive, randomized,double-blind,controlled trial will evaluate the efficacy and safety of Yinhu Qingwen Granula in patients hospitalized with severe CoVID-19.

Condition or disease	Intervention/treatment	Phase
COVID-19; Severe Pneumonia; Chinese Medicine	Drug: Yinhu Qingwen Granula; Drug: Yin Hu Qing Wen Granula(low does); Other: standard medical treatment	Phase 2; Phase 3

Detailed Description:

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.The clinical spectrum of CoVID-19 infection appears to be wide,including asymptomatic infection, mild upper respiratory disease, severe viral pneumonia with respiratory failure, and even death. However,there is no specific antiviral therapy for CoVID-19 infection, which provides a window of opportunity for testing candidate antiviral therapies. Previous experiences with SARS and MERS-CoV, highlight the need of the early intervention with Chinese medicine, and so as for CoVID-19 infection. The treatment of Chinese medicine for CoVID-19 infection suggested its benefits to improve of clinical outcomes, reduce the risk of disease progression, accelerate recovery, and reduce intensive supportive care and long-term hospitalization.Yinhu Qingwen Granula was a kind of herbal granula made from "Yinhu Qingwen Decoction", which consists of 11 common non-toxic traditional Chinese medicine such as Polygonum cuspidatum, Honeysuckle, Nepeta, Ligustrum lucidum. Previous vivo antiviral studies showed its activity for the inbition of CoVID-19. This clinical trial is planned to evaluate the improvement of the changes in the ratio of PaO2 to FiO2 from the baseline for patients with severe CoVID-19 as the primary outcome, and to evaluate the effect of the symptoms relief and virus clearance as well as the clinical safety.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 116 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Prevention
• Official Title: An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
• Estimated Study Start Date: November 2021
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: April 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Yinhu Qingwen Granula Group; Based on the standard medical treatment, the patients will be given Yinhu Qingwen Granula for 10 days.	Drug: Yinhu Qingwen Granula; Yinhu Qingwen Granula is a kind of herbal granula made from "Yinhu Qingwen Decoction", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.; Other: standard medical treatment; Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
Placebo Comparator: Yinhu Qingwen Granula Low-dose Group; Based on the standard medical treatment, the patients will be given 10% dose of Yinhu Qingwen Granula for 10 days.	Drug: Yin Hu Qing Wen Granula(low does); This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).; Other: standard medical treatment; Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.

Outcome Measures

Primary Outcome Measures :

1. changes in the ratio of PaO2 to FiO2 from baseline [ Time Frame: Day 10 ]

Secondary Outcome Measures :

1. PaO2 [ Time Frame: up to 30 days ]
2. blood oxygen saturation (SpO2) [ Time Frame: up to 30 days ]
3. clinical status rating on the 7-point ordinal scale [ Time Frame: up to 30 days ]
   The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
4. Time to Clinical Improvement (TTCI) [ Time Frame: up to 30 days ]
   TTCI is defined as the time (in days) from initiation of study treatment (Yinhu Qingwen Granula or its low-dose granula) until a decline of two categories from status at randomisation on the 7-point ordinal scale of clinical status which ranges from 0 (death) to 6 (Not hospitalized, no limitations on activities).
5. Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use [ Time Frame: up to 30 days ]
6. Duration (hours) of invasive mechanical ventilation use [ Time Frame: up to 30 days ]
7. Duration (hours) of extracorporeal membrane oxygenation (ECMO) use [ Time Frame: up to 30 days ]
8. Duration (days) of Oxygen use [ Time Frame: up to 30 days ]
9. The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment [ Time Frame: Day 10 ]
10. The counts/percentage of Lymphocyte [ Time Frame: up to 30 days ]
11. Time to hospital discharge with clinical recovery from the randomisation [ Time Frame: up to 30 days ]
12. The incidence of critical status conversion in 30 days [ Time Frame: up to 30 days ]
    Critical status is defined as: 1) respiratory failure with the need of invasive mechanical ventilation; or 2) shock; or 3) other system organ failure with ICU admission.
13. All-cause mortality within 30 days [ Time Frame: up to 30 days ]
14. Frequency of severe adverse drug events [ Time Frame: up to 30 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age ≥18 years at time of signing Informed Consent Form;
2. Those who meet the diagnosis of severe new coronavirus pneumonia with laboratory confirmed infection with CoVID-19;
3. Lung involvement confirmed with chest imaging;
4. Hospitalized with a Pa02/Fi02 ratio ≤300mgHg;
5. 40%> lymphocyte percentage ≥5%;
6. No difficulty swallowing oral medications.

Exclusion Criteria:

1. Allergies, those who are known to be allergic to research drugs or drug excipients;
2. The patient weighs less than 40 kg;
3. Patients with diarrhea;
4. Shock;
5. Patients with respiratory failure at the time of enrollment who need invasive mechanical ventilation;
6. The clinician judges that ICU admission is needed;
7. Patients who participated in other clinical trials within 1 month;
8. Known patients with impaired renal function (estimated creatinine clearance <60 mL / min (male: Cr (ml / min) = (140-age) × body weight (kg) / 72 × blood creatinine concentration (mg / dl); female: Cr (ml / min) = (140-age) × weight (kg) / 85 × blood creatinine concentration (mg / dl));
9. During the screening or within 24 hours before screening, patients were found to have any of the following laboratory parameter abnormalities (based on the local laboratory reference range): ALT or AST level> 5 times the upper limit of normal range (ULN) or ALT or AST level> 3 times ULN and total bilirubin levels> 2 times ULN;
10. Being pregnant or breastfeeding, or having a positive pregnancy test at the time of pre-dose inspection, or planning to become pregnant within 3 months after study treatment;
11. Will be transferred to another hospital which is not the study site within 72 hours.

Contacts and Locations

Locations

China, Hubei

Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital

Wuhan, Hubei, China, 430071

Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital

Wuhan, Hubei, China, 430071

Zhongnan Hospital of Wuhan University/Tanshan People's Hospital

Wuhan, Hubei, China, 430071

Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University

Wuhan, Hubei, China, 430200

Sponsors and Collaborators

Zhong Wang

Wuhan Leishenshan Hospital

The First Affiliated Hospital of Dalian Medical University

Tanshan People's Hospital

North China University of Science and Technology Affiliated Hospital

Jizhong Energy Fengfeng Group Hospital

Investigators

• Principal Investigator: Dong Shang, M.D.; Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University
• Principal Investigator: Jiang-Rong Huang, M.D.; Yangtze University Health Science Center
• Principal Investigator: Xiao-Dong Li, M.D.; Hubei Hospital of Traditional Chinese Medicine
• Study Director: Zhong Wang, M.D.; China Academy of Chinese Medical Sciences

More Information

• Responsible Party: Zhong Wang, Professor, China Academy of Chinese Medical Sciences
• ClinicalTrials.gov Identifier: NCT04310865
• Other Study ID Numbers: YHQW-Severe-V2.0
• First Posted: March 17, 2020
• Last Update Posted: July 7, 2021
• Last Verified: July 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases